Active Ingredient History

  • Now
Orteronel (TAK-700) is a nonsteroidal CYP17A1 inhibitor that was being developed for the treatment of cancer by Takeda Pharmaceutical Company in conjunction with Millennium Pharmaceuticals. It completed two phase III clinical trials for metastatic, hormone-refractory prostate cancer but failed to extend overall survival rates, and development was voluntarily terminated as a result.   Wikipedia

  • SMILES: CNC(=O)c1ccc2cc(ccc2c1)[C@@]3(O)CCn4cncc34
  • Mol. Mass: 307.35
  • ALogP: 2.04
  • ChEMBL Molecule:
More Chemistry
6-((7s)-7-hydroxy-6,7-dihydro-5h-pyrrolo(1,2-c)imidazol-7-yl)-n-methyl-2-naphthamide | orteronel | orteronel, (r)- | tak-700


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue